CD79A and nasopharyngeal carcinoma: 17 found that 19 of 22 false positives in EBNA1/IgA and VCA/IgA results were normal in the EA/IgA assessment, suggesting that combing EA/IgA with EBNA1/IgA and VCA/IgA may increase the specificity of NPC screening. In this study, the antibodies specific for the four recombinant EA proteins (Zta, TK, EA‐D‐p54, and EA‐R‐p38) were detected in 46 screened NPC patients and 263 serologically defined high‐risk subjects using the combination of EBNA1/IgA and VCA/IgA from the previous screening program 25.